Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup Study

Journal of Rheumatology

Volumn 40, Issue 10, 2013, Pages 1712-1718

  Durnez, Anne ^a,b   Paternotte, Simon ^a   Fechtenbaum, Jacques ^a   Landewé, Robert B M ^c,d   Dougados, Maxime ^a   Roux, Christian ^a   Briot, Karine ^a  

^a Institut Cochin   (France)

^b AZ Groeninge   (Belgium)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

Author keywords

Anti tumor necrosis factor; Bone mineral density; Osteoporosis; Spondyloarthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; GREATER TROCHANTER; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPHYTE; OSTEOPOROSIS; PRIORITY JOURNAL; SPONDYLARTHRITIS; SYNDESMOPHYTE;

ANTI-TUMOR NECROSIS FACTOR; BONE MINERAL DENSITY; OSTEOPOROSIS; SPONDYLOARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BONE DENSITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; IMMUNOGLOBULIN G; LUMBAR VERTEBRAE; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885143496     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121417     Document Type: Article

References (32)

1. Calin A. Osteoporosis and ankylosing spondylitis. Br J Rheumatol 1991;30:318-9.
2. Reid DM, Nicoll JJ, Kennedy NS, Smith MA, Tothill P, Nuki G. Bone mass in ankylosing spondylitis. J Rheumatol 1986;13:932-5.
3. Baek HJ, Kang SW, Lee YJ, Shin KC, Lee EB, Yoo CD, et al. Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005;26:30-4.
4. El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999;26:2205-9.
5. Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009;44:772-6.
6. Vosse D, Landewé R, van der Heijde D, van der Linden S, van Staa TP, Geusens P. Ankylosing spondylitis and the risk of fracture: Results from a large primary care-based nested case control study. Ann Rheum Dis 2009;68:1839-42.
7. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:335-9.
8. Ralston SH, Urquhart GD, Brzeski M, Sturrock RD. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990;300:563-5.
9. Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey E V, Spector TD. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-21.
10. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Fracture risk in patients with ankylosing spondylitis: A population based study. J Rheumatol 1994;21:1877-82.
11. El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M. Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 1999;26:2205-9.
12. Toussirot E, Michel F, Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 2001;40:882-8.
13. Gratacos J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M, et al. Significant bone mass in patients with early, active ankylosing spondylitis. Arthritis Rheum 1999;42:2319-24.
14. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: A two-year follow-up study. Osteoporos Int 2001;12:605-9.
15. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
16. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-82.
17. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003;62:347-9.
18. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-a treatment. J Rheumatol 2008;35:855-61.
19. Dougados M, van der linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
21. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, et al. Measuring disease activity in ankylosing spondylitis: Patient and physician have different perspectives. Rheumatology 2005;44:789-95.
22. van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
23. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11:984-96.
24. Haugeberg G, Bennett AN, McGonagle D, Emery P, Marzo-Ortega H. Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: A 1-year observational study. Ann Rheum Dis 2010;69:1364-6.
25. Vosse D, Landewé R, Garnero P, van der Heijde D, van der Linden S, Geusens P. Association of markers of bone and cartilage degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology 2008;47:1219-22.
26. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 2005;64:1137-40.
27. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001;83:70-83.
28. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, et al. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun 2007;356:1004-10.
29. Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian JC. TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 2010;25:1616-26.
30. Lories R, Derese I, De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
31. Marcora S, Casanova F, Williams E, Jones J, Elamanchi R, Lemmey A. Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis. Rheumatology 2006;45:1385-8.
32. de Vlam, Mielants H, Veys EM. Involvement of the zygapophyseal joint in ankylosing spondylitis: Relation to the bridging syndesmophyte. J Rheumatol 1999;26:1738-45